Skip to main content
Plexision’s Pharmacokinetics (PK)/Pharmacodynamics (PD) solutions presented at Cambridge Healthtech
11, Nov 2013

Plexision’s Pharmacokinetics (PK)/Pharmacodynamics (PD) solutions presented at Cambridge Healthtech...

Novel antibody-drug conjugates (ADC), some with dual cellular targets, are revolutionizing the delivery of potentially toxic chemotherapy or immunosuppressants to patients with malignancies or autoimmune diseases. Aimed at delivering drug or an innate immune effector cell, along with a biospecific antibody to the diseased tissue, these novel constructs target cellular receptors whose expression may differ between species and tissues. Such differences pose challenges to designing preclinical studies to predict safe dose-escalation or toxicity in early development, or to optimizing post-marketing efficacy of a newly approved drug. These challenges support greater use of human cell-based disease simulations for PK/PD modeling, and characterization of individual differences in drug effect from the outset. In such simulations, the need for surrogate markers of disease and response to therapy has never been greater.

Intro the presentation can be found on CHI's site here. Additional details will be posted when available.

Plexision uses PK/PD modeling in (human) cell-based disease models to predict effective drug concentration ranges for immunological disorders.

Cambridge Healthtech Institute (CHI) is the leader in conference and event development and management for the life sciences industry.


Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.